BBOT

Elite Trades From Anywhere Elite Trades All Summer

$100 Off Your First Year Get Elite For Just $199.50

Days

Hours

Mins

Sec

Claim Now

Peers: IDYA RCUS CGON KYMR TNGX NUVL RYTM BMRN INCY KRYS

| Held by: XBI VXF IBB SCHA CANC BBC SCHB LABU SGRW PWS

Scroll to Statements

Index	-
Market Cap	649.67M
Enterprise Value	400.03M
Income	-124.74M
Sales	0.00M
Book/sh	4.65
Cash/sh	3.15
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	92
IPO	Feb 09, 2024

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	1.74
P/C	2.58
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	6.16
Current Ratio	6.16
Debt/Eq	0.01
LT Debt/Eq	0.01
Option/Short	No / Yes

EPS (ttm)	-527.59
EPS next Y	-2.20
EPS next Q	-0.56
EPS this Y	46.23%
EPS next Y	4.80%
EPS next 5Y	19.33%
EPS past 3/5Y	-2681.49% -572.84%
Sales past 3/5Y	- -
EPS Y/Y TTM	-206431.48%
Sales Y/Y TTM	-
EPS Q/Q	-2541516.43%
Sales Q/Q	-
Earnings	May 12 AMC
EPS/Sales Surpr.	-2.75% -

Insider Own	45.80%
Insider Trans	0.00%
Inst Own	46.31%
Inst Trans	-1.35%
ROA	-40.68%
ROE	-44.51%
ROIC	-33.32%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	5.87%
SMA50	-0.48%
SMA200	-22.32%
Trades

Shs Outstand	80.09M
Shs Float	43.41M
Short Float	9.08%
Short Ratio	8.51
Short Interest	3.94M
52W High	14.87 -45.46%
52W Low	7.00 15.86%
Volatility	7.02% 6.59%
ATR (14)	0.52
RSI (14)	54.19
Beta	0.37
Rel Volume	0.87
Avg Volume	462.89K
Volume	401,380

Perf Week	5.46%
Perf Month	-1.93%
Perf Quarter	-10.19%
Perf Half Y	-34.44%
Perf YTD	-35.22%
Perf Year	-23.49%
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.10
Target Price	25.11
Prev Close	7.80
Price	8.11
Change	3.97%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-22-26	Resumed	Oppenheimer	Outperform	$22
May-11-26	Initiated	Canaccord Genuity	Buy	$23
Feb-11-26	Initiated	Stifel	Buy	$23
Jan-09-26	Initiated	Raymond James	Outperform	$24
Dec-05-25	Initiated	Morgan Stanley	Overweight	$20
Sep-17-25	Initiated	Leerink Partners	Outperform	$25
Sep-15-25	Initiated	H.C. Wainwright	Buy	$27
Aug-15-25	Initiated	Piper Sandler	Overweight	$21

May-12-26 05:03PM	BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress (GlobeNewswire)
04:05PM	BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-24-26 06:46AM	Lilly tumbles on Foundayos shaky week; FDA to issue vouchers for psychedelics (BioPharma Dive)
Apr-22-26 04:05PM	BBOT Presents Preclinical Data Demonstrating pan-KRAS Inhibitor BBO-11818 Has Robust Anti-Tumor Activity in KRAS-Mutant Preclinical Models at the AACR Annual Meeting 2026 (GlobeNewswire) -6.24%
09:00AM	BBOT Announces the Appointment of Pedro J. Beltran, PhD, as Chief Executive Officer, Idan Elmelech as Chief Operating Officer, and Neil Kumar, PhD, as Executive Chairman (GlobeNewswire)
05:30PM	Loading…
Apr-21-26 05:30PM	BBOT Presents Preclinical Data Showing RAS:PI3Ka Breaker BBO-10203 Inhibits PI3Ka/AKT Signaling in HER2AMP Models at the AACR Annual Meeting 2026 (GlobeNewswire)
Apr-20-26 04:06PM	BBOT Granted U.S. FDA Fast Track Designation for BBO-11818 for the Treatment of Adult Patients with Advanced KRAS-Mutant Pancreatic Ductal Adenocarcinoma (GlobeNewswire)
Apr-13-26 04:05PM	BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.55%
Mar-18-26 04:05PM	BBOT Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026 (GlobeNewswire) -6.33%
Mar-06-26 10:07AM	BBOT Announces Publication in Cancer Discovery Highlighting Preclinical Data Demonstrating BBO-11818 is a Potent and Selective panKRAS Inhibitor (GlobeNewswire) +5.36%
Mar-05-26 04:05PM	BBOT Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress (GlobeNewswire)
Feb-25-26 10:10PM	BridgeBio Oncology Touts Best in RAS Pipeline, Highlights BBO-8520 Response and Combo Tolerability (MarketBeat)
Feb-12-26 04:05PM	BBOT to Participate in Upcoming Investor Healthcare Conferences (GlobeNewswire) -5.15%
Feb-11-26 04:05PM	BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +11.07%
07:50AM	Here Are Wednesdays Top Wall Street Analyst Research Calls: BP Plc., Cloudflare, Dicks Sporting Goods, Mattel, Noble Corp., Qualcomm, Tyler Technologies, XPO, and More (24/7 Wall St.)
04:05PM	Loading…
Jan-13-26 04:05PM	BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -9.16%
Jan-07-26 07:00AM	BBOT Announces New Clinical Data Advancing Its Portfolio of Three Innovative and Differentiated RAS and PI3Ka Pipeline Programs (GlobeNewswire)
Dec-16-25 04:05PM	BBOT to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-11-25 04:05PM	BBOT Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-10-25 04:05PM	BBOT Announces Late-Breaking Preclinical Data on BBO-10203, a First-in-Class RAS:PI3Ka Breaker, at the San Antonio Breast Cancer Symposium (SABCS) (GlobeNewswire)
Nov-18-25 04:05PM	BBOT to Participate in Upcoming December Investor Healthcare Conferences (GlobeNewswire) -5.93%
Nov-12-25 04:05PM	BBOT Reports Third Quarter 2025 Financial Results and Update on Corporate Progress (GlobeNewswire)
Nov-03-25 04:05PM	BBOT to Participate in the Jefferies Global Healthcare Conference in London (GlobeNewswire)
Oct-30-25 05:45PM	BBOT Announces Poster Presentations at the San Antonio Breast Cancer Symposium (SABCS) (GlobeNewswire)
Oct-25-25 12:30PM	Preclinical Data Presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Support Potential of BBO-10203, a First-in-Class RAS:PI3Ka Breaker That Inhibits KRAS-Mutant Tumor Growth without Inducing Hyperglycemia (GlobeNewswire)
Oct-23-25 04:05PM	BBOT Presents Preclinical Data Demonstrating Potential of BBO-11818 as a Potent panKRAS Inhibitor at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Oct-13-25 04:05PM	BBOT Announces Poster Presentations at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Aug-20-25 08:00AM	BBOT to Participate in Upcoming September Investor Healthcare Conferences (GlobeNewswire) -5.59%
Aug-06-25 07:33AM	Helix Acquisition Corp. II Retains More than 60% of Trust Account after Redemptions in connection with Business Combination with BridgeBio Oncology Therapeutics (GlobeNewswire) +8.09%
Jul-11-25 07:43AM	Helix Acquisition Corp. II and BridgeBio Oncology Therapeutics Announce Effectiveness of Registration Statement for Proposed Business Combination (GlobeNewswire)
07:16AM	Loading…
Mar-03-25 07:16AM	BridgeBio Oncology and Helix enter definitive merger agreement (Pharmaceutical Technology)
Feb-28-25 07:49AM	BridgeBio Oncology Therapeutics (BBOT) and Helix Acquisition Corp. II Announce Business Combination Agreement to Create Publicly Listed Biotechnology Company Advancing a Pipeline of RAS and PI3Ka-Targeting Medicines (Business Wire)
Feb-29-24 03:01AM	5 Stocks With Heavy Insider Buying In 2024 (Insider Monkey)
Feb-14-24 07:30AM	Helix Acquisition Corp. II Announces Closing of $184 Million Initial Public Offering, Including the Full Exercise of the Underwriter's Option to Purchase Additional Shares (Business Wire)
Feb-09-24 07:30AM	Helix Acquisition Corp. II Announces Pricing of Upsized $160 Million Initial Public Offering (Business Wire)

Bridgebio Oncology Therapeutics, Inc. engages in developing bioavailable small molecule inhibitors. It focuses on advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Ka malignancies. The company was founded on August 1, 2016 and is headquartered in South San Francisco, CA.

Executive ChairmanDr. Neil Kumar Ph.D.

Co-FounderDr. Frank P. McCormick Ph.D.

M.D.Dr. Yong Ben M.B.A.

Ph.D.Dr. Pedro J. Beltran M.D.

VP of Finance & ControllerMr. Marc Cobo

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

$100 Off Your First Year Get Elite For Just $199.50

BridgeBio Oncology Therapeutics Inc

Upgrade your Finviz experience